Latin American Clinical Practice Guidelines on the Systemic Treatment of PsoriasisSOLAPSO – Sociedad Latinoamericana de Psoriasis(Latin American Psoriasis Society)
| Autor: | Evelyn G Castro Vargas, Carla Castro, Jaime E Martínez López, Lilia Barahona-Torres, Jorge A Abarca Duran, Manuel Franco, Juan Carlos os Diez de Medina, Juan Martín Criniti, Verónica P Levrero, Nora Kogan, Gerardo B Quintana, Minerva Gómez, Fernando Valenzuela, Simon Eduardo Gusis, Ariel Izcovich, Nélida Raimondo, Orestes Blanco, María C Briones |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Injections Subcutaneous Psychological intervention MEDLINE Administration Oral Dermatology Severity of Illness Index law.invention 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Quality of life (healthcare) Randomized controlled trial law Psoriasis Severity of illness medicine Humans Societies Medical Enfermedades de la piel Biological Products business.industry Guideline Phototherapy medicine.disease Guía de práctica clínica Latin America 030220 oncology & carcinogenesis Family medicine Observational study Dermatologic Agents business |
| Zdroj: | Repositorio U. El Bosque Universidad El Bosque instacron:Universidad El Bosque |
| ISSN: | 1365-4632 0011-9059 |
| Popis: | This Clinical Practice Guideline on the systemic treatment of Psoriasis includes the recommendations elaborated by a panel of experts from the Latin American Psoriasis Society SOLAPSO, who assessed the quality of the available evidence using the GRADE system and the PICO process to guide the literature search. To answer each question, the experts discussed the results of randomized controlled trials, observational studies and metanalysis evaluating the interventions identified (non-biologics, biologics and phototherapy) in different populations of patients with moderate to severe plaque-psoriasis, which was summarized in Tables ad-hoc. The main end-points considered to assess efficacy were PASI 50, 75, 90 and 100, PGA 0-1 and significant improvement of health-related quality of life. Specific adverse events, either severe or leading to treatment interruption, were also evaluated. The 31 recommendations included in this CPG follow the structure proposed by GRADE: direction (for or against) and strength (strong or weak). The goal of this CPG is to improve the management of patients with psoriasis by recommending interventions of proved benefit and providing a reference standard for the treating physician. Adhering to the contents of this CPG does not guarantee therapeutic success. The final decision on the specific treatment is the responsibility of the physician based on the individual circumstances and considering the values, the preferences and the opinions of the patient or caregivers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text